New Edge Advisors, LLC Apellis Pharmaceuticals, Inc. Transaction History

New Edge Advisors, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 15, 2024	SELL	$38.07 - $59.71 $6,700 - $10,508	-176 Reduced 77.88%	50 $1,000
Q1 2024 May 14, 2024	SELL	$55.39 - $72.47 $1,495 - $1,956	-27 Reduced 10.67%	226 $13,000
Q4 2023 Feb 13, 2024	BUY	$37.14 - $64.82 $9,396 - $16,399	253 New	253 $15,000
Q4 2022 Feb 14, 2023	BUY	$43.24 - $61.04 $8,648 - $12,208	200 New	200 $10,000

319

123M

3.57M

778K

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $2.23B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of New Edge Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on New Edge Advisors, LLC with notifications on news.